Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

42.17 +5.86 (+16.14%)

Streaming Delayed Price Updated: 11:01 AM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT). ↗

December 12, 2024

Exploring high growth characteristics of CORCEPT THERAPEUTICS INC (NASDAQ:CORT).

Via Chartmill

NASDAQ:CORT, a strong growth stock, setting up for a breakout. ↗

December 12, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

December 11, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating ↗

December 11, 2024

NewAmsterdam Pharma stock saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 74 to 95.

Via Investor's Business Daily

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

November 28, 2024

NASDAQ:CORT is showing decent growth, but is still valued reasonably.

Via Chartmill

In the world of growth stocks, NASDAQ:CORT shines as a value proposition. ↗

November 04, 2024

Looking for growth without the hefty price tag? Consider NASDAQ:CORT.

Via Chartmill

Earnings Preview: Corcept Therapeutics ↗

October 29, 2024

Via Benzinga

Key Takeaways From Corcept Therapeutics Analyst Ratings ↗

October 18, 2024

Via Benzinga

Is NASDAQ:CORT suited for high growth investing? ↗

October 17, 2024

Should you consider CORCEPT THERAPEUTICS INC (NASDAQ:CORT) for high growth investing?

Via Chartmill

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

October 30, 2024

Via Benzinga

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update

October 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 23, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

October 14, 2024

Is CORCEPT THERAPEUTICS INC (NASDAQ:CORT) on the Verge of a Major Breakout as a Strong Growth Stock?

Via Chartmill

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗

October 08, 2024

NASDAQ:CORT is not too expensive for the growth it is showing.

Via Chartmill

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics ↗

September 18, 2024

Via Benzinga

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

September 09, 2024

Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.

Via Chartmill

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗

September 30, 2024

Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...

Via Benzinga

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

September 17, 2024

Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

August 27, 2024

Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

August 16, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

August 05, 2024

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Unveiling 8 Analyst Insights On Corcept Therapeutics ↗

July 30, 2024

Via Benzinga

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

July 29, 2024

CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 29, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 22, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

July 15, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗

July 15, 2024

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

Via Chartmill

7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗

June 26, 2024

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

Via InvestorPlace

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗

June 26, 2024

Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.

Via InvestorPlace

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

June 24, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.